Dr Thomas Parr has been appointed chief scientific officer of Targanta Therapeutics Inc (formerly PhageTech Inc), a private biopharmaceutical firm developing new classes of antibiotics based on its work with phage genomics (bacterial viruses). Parr was formerly with Adaptive Therapeutics, VP R&D at Embiosis Pharmaceuticals and senior director of microbiology with Xenogen Corp. He holds a PhD from the Univ of Calgary….
Other stories mentioning these organizations, people and topics
| People: | Dr Daniel Podolsky, Dr Pat Jamieson, Dr Ronald Bond, Dr Ted Hewitt, Dr Thomas Parr, Garold G. Breit, and Marcel Chartrand |
Other News
Events For Leaders in
Science, Tech, Innovation, and Policy
Discuss and learn from those in the know at our virtual and in-person events.
See Upcoming Events
You have 1 free article remaining.
Don't miss out - start your free trial today.
Start your FREE trial Already a member? Log in
By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.